Efficacy and Safety of Switching Latanoprost Monotherapy to Bimatoprost Monotherapy or Combination of Brinzolamide and Latanoprost

Mitsuhiro Imasawa1, 2, Joji Tanabe3, Fumiko Kashiwagi4, Kenji Kashiwagi2, *
1 Department of Ophthalmology, Nirasaki Municipal Hospital, Nirasaki, Yamanashi, Japan
2 Department of Ophthalmology, Faculty of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan
3 Tanabe Eye Clinic, Kai, Yamanashi, Japan
4 Kashiwagi Eye Clinic, Kofu, Yamanashi, Japan

Article Metrics

CrossRef Citations:
Total Statistics:

Full-Text HTML Views: 4160
Abstract HTML Views: 2191
PDF Downloads: 761
ePub Downloads: 620
Total Views/Downloads: 7732
Unique Statistics:

Full-Text HTML Views: 2007
Abstract HTML Views: 1267
PDF Downloads: 533
ePub Downloads: 446
Total Views/Downloads: 4253

Creative Commons License
© Imasawa et al.; Licensee Bentham Open.

open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) (, which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.

* Address correspondence to this author at the Department of Ophthalmology, Faculty of Medicine, University of Yamanashi, Shimokato 1110, Chuo, Yamanashi, 409-3898, Japan; Tel: +81 55 273 9657; Fax: +81 55 273 6757; E-mail:



To prospectively assess the efficacy and safety of switching to bimatoprost monotherapy or brinzolamide and latanoprost combination therapy in patients who had been receiving latanoprost monotherapy.


A prospective, open-label study was conducted. Patients with primary open-angle glaucoma or ocular hypertension who had been receiving latanoprost monotherapy for three months or more were enrolled. Bimatoprost was substituted for latanoprost in one eye (BIM group), and brinzolamide was added to the latanoprost in the other eye (BRZ group) simultaneously. The patients underwent examinations at 6 weeks (visit 1) and 12 weeks (visit 2) after changing therapies. Subsequently, the treatments were returned to latanoprost monotherapy. The patients underwent another examination 6 weeks (visit 3) after the return to latanoprost. The parameters examined were intraocular pressure (IOP), conjunctival hyperemia, and corneal epithelial damage.


Twenty-six patients (13 men and 13 women) completed the protocol. Both groups showed a significant IOP reduction at visits 1 and 2 compared with the baseline, with a similar magnitude (BIM group: P = 0.016 at visit 1, P = 0.025 at visit 2, BRZ group: P = 0.0006 at visit 1, P = 0.028 at visit 2). The IOPs at the baseline and on visit 3 were similar in both groups (P = 0.7). The two groups showed no changes in either conjunctival hyperemia or corneal epithelial damage compared with the baseline.


Bimatoprost monotherapy and brinzolamide adjunctive to latanoprost similarly reduced the IOP, with no additive adverse effects, compared with latanoprost monotherapy.

Keywords: Bimatoprost, Brinzolamide, Glaucoma, Intraocular Pressure, Latanoprost.